Letter to the Editor
Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors’ reply
A. Cortegiania,b,
, M. Ippolitoa, S. Einavc
Corresponding author
andrea.cortegiani@unipa.it
Corresponding author at: Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, Italy.
Corresponding author at: Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, Italy.
a Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, Italy
b Department of Anesthesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, University of Palermo, Palermo, Italy
c Intensive Care Unit of the Shaare Zedek Medical Medical Centre, Hebrew University Faculty of Medicine, Jerusalem, Israel
